KRAS Companion Test for Erbitux Wins OK

(MedPage Today) — A rapid molecular test for KRAS mutations has received FDA approval as an aid in identifying colorectal cancer patients who would benefit from cetuximab (Erbitux) treatment.

Post a Comment

Comments are closed.